RxDoctor Payments Data

Clint Lincoln, MD

Family Medicine · Lake Charles, LANPI 1194081414

Payments from drug & device makers

$2,169in general payments, 2019–2025

Across 118 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$988
  • AstraZeneca$315
  • Pfizer$273
  • Biohaven Pharmaceuticals, Inc.$125
  • Boehringer Ingelheim$98
  • GSK$95
  • plus $275 from 8 others

What the payments were for

  • Food & beverage$2,15799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,169 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$75,270
Medicare patients
200
Services billed
1,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$84,816
MounjaroTirzepatide64$79,620
EliquisApixaban47$68,335
JardianceEmpagliflozin49$60,105
TrulicityDulaglutide35$49,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$48,689
VraylarCariprazine Hcl22$34,010
XareltoRivaroxaban32$32,460
Nurtec OdtRimegepant Sulfate15$24,915
FarxigaDapagliflozin Propanediol16$22,540
JanuviaSitagliptin Phosphate12$17,806
LinzessLinaclotide11$16,924
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,782
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$5,524
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$273$93,25062 claims
Novo NordiskOzempic$14$84,81658 claims
Boehringer IngelheimJardiance, Stiolto Respimat$98$68,88760 claims
GSKTrelegy Ellipta, Anoro Ellipta$95$53,91473 claims
AbbVieVraylar, Linzess$988$50,93433 claims
AstraZenecaFarxiga, Symbicort$315$26,72432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →